SOD1 and amyotrophic lateral sclerosis: Although relatively novel, there are multiple FDA-approved ASO therapies for a range of conditions such as Batten disease, Duchenne muscular dystrophy, hereditary transthyretin-mediated amyloidosis, SMA and very recently SOD1-ALS.